Facephi Biometria SA (FACE)
Madrid Stock Exchange · Spain · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 1.800 |
|---|---|
| 52-week range | 1.355 – 2.880 |
| Return, 1 month / 3 months | +21.6% / +3.2% |
| Return, 1 year / 3 years | −29.4% / −17.8% |
| Trend | Below its 200-day average |
| RSI (14) | 56 |
| Volatility (1 year) | 41.2% |
| Worst drawdown (1 year) | -49.6% |
| Average daily value traded | 0.03M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
FacePhi Biometria is a Spanish technology company that develops biometric authentication software, with facial recognition at the centre of its offering. Its products let organisations verify a person's identity through a mobile device or camera, supporting digital onboarding and secure access to services. Banks, financial institutions and other organisations use its tools to confirm that customers are who they claim to be. The company is based in Alicante, Spain, and its software is used in markets across several countries.
On this site Facephi Biometria SA appears as a stock on the Madrid Stock Exchange (Spain), code FACE, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Facephi Biometria SA (FACE) trades on the Madrid Stock Exchange in Spain. It last closed at EUR 1.800 on 27 October 2026.
Its price-based Market X-Ray is 26 out of 100 (a weak price profile), ranking 204 of 236 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 29.4% and over the last three months it rose 3.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Madrid Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 14 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -11.6% | ||
| From 52-week high | -35.9% | ||
| Momentum | 37 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 3.2% | ||
| 6-month return | -17.4% | ||
| 12-month return, skipping the last month | -42.0% | ||
| Stability (higher is calmer) | 13 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -49.6% | ||
| Liquidity | 51 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.03M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +4.7% |
|---|---|
| 1 month | +21.6% |
| 3 months | +3.2% |
| 6 months | −17.4% |
| 1 year | −29.4% |
| 3 years | −17.8% |
| 5 years | −61.2% |
Signals
| 50-day / 200-day average | 1.710 / 2.036 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.073 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Madrid Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.